News

According to interim results from a phase 3 study, the addition of apalutamide to androgen deprivation therapy showed a statistically and clinically significant improvement of PSA progression-free survival among patients with high-risk...

Study results demonstrated that ‘second adjuvant’ therapy with a BRAF/MEK inhibitor improved recurrence-free survival at the cost of toxicity among patients with BRAF-mutated melanoma who experienced disease recurrence after treatment with an...

Based on results from the phase 3 FLAURA 2 trial, the FDA has approved osimertinib plus platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 19 deletions or exon 21 L858R...

The FDA has granted an accelerated approval to lifileucel for patients unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600-positive, a BRAF inhibitor with or without a MEK inhibitor.

Results from a retrospective cohort study found that antibiotic exposure within 60 days prior to initiation of immune checkpoint blockade was associated with worse PFS and OS among patients with treatment-naïve cutaneous or mucosal melanoma.

A study by Haojie Li, MD, PhD, and colleagues evaluated real-world treatment patterns and overall survival for patients with mUC during the period between the approval of maintA and P+EV for use in the US.

A recent study investigated real-world outcomes of brexu-cel treatment in patients with relapsed or refractory mantle cell lymphoma with high-risk features, including deletion of TP53 or 17p, Ki-67 proliferation index, and whether the...

The US Food and Drug Association has granted approval to irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin for the treatment of patients with metastatic pancreatic adenocarcinoma in the first-line setting.

Results from a retrospective cohort study found that molecular classification can predict prognosis and relapse patterns among patients with low or intermediate-risk endometrial cancer.

Get a summary of the changes in the NCCN guidelines regarding radiopharmaceuticals, secondary hormone therapy, and treatments for metastatic castration-sensitive prostate cancer.